AstraZeneca Results Presentation Deck

Total Revenue | +4% H1 2022 Strong commercial performance and financial execution in H1 2023 +16% Ex-COVID-19 Total Revenue Benefitting from broad-based, diverse source of revenue H1 2023 CEO Opening Remarks Vaxzevria/COVID-19 mAbs¹ Total Revenue Core EPS +21% H1 2022 $4.07 Financial Results H1 2023 Oncology BioPharmaceuticals Oncology 39% Broad-based, diverse source of revenue Rare Disease H1 2023 % Total Revenue by therapy area R&I V&I Other 14% 3% 3% CVRM 24% H1 2023 % Total Revenue by geography US Europe 41% 20% CEO Closing Remarks Emerging Markets 28% All growth rates at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 5 1. COVID-19 mAbs = Evusheld and AZD3152, the antibody currently in development. CER = constant exchange rates; EPS = earnings per share; CVRM = Cardiovascular, Renal & Metabolism; R&I= Respiratory & Immunology; V&I = Vaccines & Immune Therapies; EROW = Established Rest of World. Rare Disease 17% EROW 12% Reiterating 2023 guidance: Core EPS to increase by a high single-digit to low double-digit %

View entire presentation